Multiple Sclerosis Mega Study
Contents
Multiple Sclerosis
Multiple Sclerosis

Related

A
1 to 5 Rating
A
Symptoms
A
Factors
A
Effects

Tags

Multiple Sclerosis
Multiple Sclerosi

Conditions Resulting from Multiple Sclerosis

User-reported conditions resulting from Multiple Sclerosis based on their intuition.

Resulting Condition Agree
Herniated Disc 87%
Plantar Fasciitis 70%
Chronic Cerebrospinal Venous Insufficiency (CCSVI) 49%
Urinary Incontinence 21%
Neurological Problems and Chronic Pain 18%
Vertigo 16%
Neuropathy 14%
Chronic Pain Syndrome 7%
Constipation 6%
Dizziness/Lightheadedness 6%
Myofascial Pain Syndrome 5%
Athlete's Foot 5%
Scoliosis 5%
Night Cramps 5%
Hearing Loss 5%
Cold Intolerance 5%
Chronic Fatigue Syndrome 4%
Fatigue 4%
Depression 3%
Rheumatoid Arthritis 3%
Shoulder Pain 3%
Tinnitus 3%
Neck Pain 3%
Back Pain 2%
Lower Back Pain 2%
Allergies 1%
Anxiety 1%
Infertility 0%
Occipital Neuritis 0%

Treatments

User-reported effectiveness in treating Multiple Sclerosis

Treatment Major Improvement Moderate Improvement Much Worse No Effect Worse Responses
Physical Therapy 13% 49% 0% 30% 8% 106
Rest 22% 52% 0% 22% 3% 203
Exercise 19% 43% 3% 29% 6% 193
Acupuncture 2% 32% 7% 54% 5% 41
Low Dose Naltrexone (LDN) 50% 32% 2% 14% 3% 125
Neurontin (Gabapentin) 11% 38% 8% 38% 5% 61
Corticosteroids 23% 45% 6% 21% 6% 107
Vitamin D 9% 22% 1% 66% 2% 125
Provigil 19% 37% 11% 27% 5% 62
Massage Therapy 22% 46% 0% 28% 4% 46
Trigger Point Injections 17% 50% 0% 17% 17% 6
Paracetamol 0% 37% 0% 60% 3% 30
Baclofen 16% 24% 3% 46% 11% 79
Xanax 17% 33% 6% 39% 6% 18
Occupational Therapy 7% 36% 5% 48% 5% 42
Estrogen Therapy 13% 25% 13% 50% 0% 8
Chinese Herbs 5% 25% 5% 65% 0% 20
Homeopathy 15% 20% 0% 60% 5% 20
Cannabis 23% 40% 4% 28% 4% 47
Diet Changes 17% 38% 2% 39% 3% 180
Tysabri 21% 21% 14% 41% 3% 29
Copaxone 9% 19% 4% 60% 9% 112
Counseling 14% 45% 2% 33% 7% 58
Ayurveda 0% 100% 0% 0% 0% 4
Celexa 8% 33% 0% 33% 25% 12
Avonex 3% 11% 28% 48% 9% 64
Pool, Water Therapy 23% 57% 0% 13% 7% 30
IV Steroids 29% 38% 6% 22% 5% 82
Acupressure 15% 77% 0% 8% 0% 13
Intravenous Solution (Calcium-EAP) 75% 0% 0% 25% 0% 4
Gilenya 50% 50% 0% 0% 0% 4
Grain/legume/dairy-Free Diet (Aka Paleo) 20% 40% 0% 40% 0% 25
Nuvigil 44% 22% 11% 11% 11% 9
CCSVI (Chonic Cerebrospinal Venous Insufficiency) 60% 0% 0% 0% 40% 5
Implanted Baclofen Pump 0% 100% 0% 0% 0% 1
Plasma Exchange 0% 67% 0% 33% 0% 3
Campath 0% 50% 0% 50% 0% 2
Bee Sting Treatment 0% 0% 0% 100% 0% 1
Tonic Water 0% 0% 0% 100% 0% 1
Tizanidine 0% 61% 0% 22% 17% 18
IVIG 50% 0% 50% 0% 0% 2
Carbamazepine 0% 40% 20% 40% 0% 5
Hyperbaric Oxygenation 0% 50% 17% 17% 17% 6
4-Aminopyridine 8% 23% 8% 54% 8% 13
Novantrone 18% 9% 18% 45% 9% 11
Cytoxan/Endoxan 0% 0% 100% 0% 0% 3
Amantadine 8% 18% 8% 50% 18% 40
Rebif 8% 16% 21% 41% 14% 63
Betaseron 0% 9% 24% 53% 15% 34

Below is the degree of change seen after Multiple Sclerosis is higher than average.

Below is the change in Multiple Sclerosis seen after the predictor is higher than average.

Outcomes
of
Below is the change in the listed outcome after is higher than average.
Sort by Effect Size
Sort by Confidence
% Change from Baseline*
*
Change in the listed outcome after is higher than average.
Predictors
of
Below is the change in after the listed predictor is higher than average.
Sort by Effect Size
Sort by Confidence
% Change from Baseline*
*
Change from the average seen after the predictor is higher than average.

Multiple Sclerosis Info

Property Value
Variable Name Multiple Sclerosis
Aggregation Method MEAN
Analysis Performed At 2020-03-02
Duration of Action 24 hours
Maximum Allowed Value 5 out of 5
Minimum Allowed Value 1 out of 5
Number of Aggregate Predictors 0
Number of Aggregate Outcomes 0
Number of Measurements 0
Number of Measurements (including those generated by tagged, joined, or child variables) 0
Public true
Onset Delay 0 seconds
Unit 1 to 5 Rating
User Variables 0
Variable Category Symptoms
Variable ID 86869